#marketrisk
GLP-1 Weight Loss Drugs Lift Pharma Profits, But Deloitte Warns of Bubble Risk
GLP-1 Drugs Drive Pharma Growth GLP-1 weight loss drugs are powering a sharp rebound in pharma R&D returns, but analysts warn the boom may be creating a risky “bubble effect” across the sector. According to Deloitte’s latest pharma innovation analysis, R&D returns among the world’s top 20 drugmakers have climbed to 7%, driven largely by obesity and diabetes treatments such as GLP-1 drugs. Obesity Drugs Overtake Oncology
GLP-1 Weight Loss Drugs Lift Pharma Profits, But Deloitte Warns of Bubble Risk
GLP-1 Drugs Drive Pharma Growth GLP-1 weight loss drugs are powering a sharp rebound in pharma R&D returns, but analysts warn the boom may be creating a risky “bubble effect” across the sector. According to Deloitte’s latest pharma innovation analysis, R&D returns among the world’s top 20 drugmakers have climbed to 7%, driven largely by obesity and diabetes treatments such as GLP-1 drugs. Obesity Drugs Overtake Oncology









